Acute Pancreatitis

Diagnosis and Prevalence

• The prevalence of idiopathic pancreatitis should be less than 20-25% of cases, emphasizing the need for a thorough etiological evaluation 1
• Subclinical pancreatic inflammation occurs in approximately 7% of inflammatory bowel disease patients, according to the European Crohn’s and Colitis Organisation 2
• Pancreatic ductal abnormalities are found in 8-16% of IBD patients, as reported by the European Crohn’s and Colitis Organisation 2
• Hypertriglyceridemia, especially when triglyceride levels exceed 1000 mg/dL, can precede the development of pancreatitis, as stated by the American Heart Association 3
• Certain medications, including thiopurines (4% of treated IBD patients), protease inhibitors, steroids, tamoxifen, and antipsychotics, can cause pancreatic inflammation, as reported by the European Crohn’s and Colitis Organisation and the American Heart Association 2, 3
• Liver disease and biliary obstruction can contribute to pancreatic inflammation, particularly in cholestatic conditions, as stated by the American College of Radiology 4

Diagnostic Criteria and Imaging

• Contrast-enhanced CT is the most comprehensive imaging modality for evaluating pancreatic pathology, according to the World Society of Emergency Surgery 5
• The American College of Radiology recommends considering imaging for persistent or significant elevations of lipase (>3× ULN) 5
• A cut-off value of three times the upper limit of normal for both amylase and lipase is recommended for diagnosis, as supported by the American College of Gastroenterology and the American Gastroenterological Association (AGA) 6, 7, 1, 8, 9
• The pattern of serum enzyme elevation in acute pancreatitis follows a specific timeline:

6

• Ultrasound is the initial test to detect gallstones, but it visualizes the pancreas poorly in 25-50% of cases, according to the American Gastroenterological Association 1
• Early CT (within first 72 hours) may underestimate pancreatic necrosis, and ultrasound can be used as an alternative, as suggested by the American Institute of Ultrasound in Medicine 1

Management and Treatment

• For traumatic causes of lipase elevation, management is based on injury grade (WSES classification), with minor injuries potentially being managed conservatively and severe injuries possibly requiring surgical intervention, according to the World Society of Emergency Surgery 5
• The American Gastroenterological Association recommends pancreatic enzyme replacement therapy (PERT) as the primary treatment for exocrine pancreatic insufficiency (EPI), with an initial dosing of 500 units of lipase per kg per meal and 250 units of lipase per kg per snack 10
• PERT should be taken during meals to maximize mixing and digestion of nutrients, with a maximum dose of 2500 units of lipase per kg per meal or 10,000 units of lipase per kg per day 10
• Enteric-coated microspheres (e.g. Creon, Zenpep, Pancreaze, Pertzye) are recommended, while non-enteric-coated tablets (e.g. Viokace) require co-treatment with an acid-reducing agent 10
• Baseline measurements of nutritional status, including BMI, quality-of-life measure, and fat-soluble vitamin levels, should be taken, with annual assessments of micronutrient status and endocrine function (glucose, HbA1c) 10
• A low-moderate fat diet with frequent smaller meals is recommended, with routine supplementation and monitoring of fat-soluble vitamin levels, and avoidance of very-low-fat diets, alcohol, and tobacco 10

Monitoring and Follow-up

• Patients with a history of pancreatitis should not be rechallenged with Ozempic, and alternative diabetes/weight management medications should be considered, according to the American Heart Association 11
• Monitor for development of exocrine pancreatic insufficiency in patients with recurrent or severe pancreatitis, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 11
• For mild elevation (<3× ULN), monitoring clinically and considering repeat testing in 2-4 weeks if symptoms persist is recommended, and for moderate elevation (3-5× ULN), consider temporarily withholding Ozempic, monitor closely for development of symptoms, repeat lipase testing in 1-2 weeks, and if levels decrease, consider cautious reintroduction at lower dose, according to the Endocrine Society and the American Association of Clinical Endocrinologists 1, 11
• For severe elevation (>5× ULN), discontinue Ozempic, consider imaging to rule out pancreatitis, and monitor until enzyme levels normalize, as recommended by the American College of Gastroenterology and the American Heart Association 11
• Primary care monitoring is appropriate for patients with mild elevations of amylase and/or lipase (less than three times the upper limit of normal), with consideration of serial enzyme monitoring and imaging if symptoms develop or worsen, as suggested by the American Gastroenterological Association (AGA) guidelines 8